CASP9 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant CASP9.
|Application ||WB, IF, E|
|Calculated MW||46281 Da|
|Other Names||Caspase-9, CASP-9, Apoptotic protease Mch-6, Apoptotic protease-activating factor 3, APAF-3, ICE-like apoptotic protease 6, ICE-LAP6, Caspase-9 subunit p35, Caspase-9 subunit p10, CASP9, MCH6|
|Target/Specificity||CASP9 (AAH02452.1, 1 a.a. ~ 416 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||CASP9 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein is processed by caspase APAF1; this step is thought to be one of the earliest in the caspase activation cascade. Alternative splicing results in two transcript variants which encode different isoforms.
Influence of caspases 8 and 9 gene promoter polymorphism on prostate cancer susceptibility and early development of hormone refractory prostate cancer. Kesarwani P, et al. BJU Int, 2010 Aug 27. PMID 20804486.Polymorphisms in the caspase genes and the risk of lung cancer. Lee SY, et al. J Thorac Oncol, 2010 Aug. PMID 20661084.Fat intake interacts with polymorphisms of Caspase9, FasLigand and PPARgamma apoptotic genes in modulating Crohn's disease activity. Ferreira P, et al. Clin Nutr, 2010 Jul 20. PMID 20650551.A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Ho-Pun-Cheung A, et al. Pharmacogenomics J, 2010 Jul 20. PMID 20644561.Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.